Thrombosis Research — Affiliation with the European Thrombosis Research Organization (ETRO)

Venous Thromboembolic Disease

“…More advanced age, a common characteristic of many cancer patients, was shown to be associated with an increased risk of VTE in some clinical settings, 1,14,21 and obesity was also identified as a risk factor. 21–24 Evidence also shows that prechemotherapy thrombocytosis, 24–26 leukocytosis, 24 and hemoglobin level less than 10 g/dL 24,25 are predictive of VTE in patients undergoing chemotherapy, although the association of anemia with VTE may be complicated by the use of erythropoietic stimulating agents.…”

“…21–24 Evidence also shows that prechemotherapy thrombocytosis, 24–26 leukocytosis, 24 and hemoglobin level less than 10 g/dL 24,25 are predictive of VTE in patients undergoing chemotherapy, although the association of anemia with VTE may be complicated by the use of erythropoietic stimulating agents. Acquired risk factors for VTE include a history of VTE and certain hypercoagulable conditions, such as pregnancy.…”

“…33 Although differences in study designs make it difficult to compare VTE rates according to specific type of malignancy, other cancers that have been associated with an increased risk of VTE include those of the stomach, kidney, uterus, lung, ovary, bladder, and testis. 1,21,31 In addition, an increased risk of VTE has been observed in certain hematologic malignancies, such as lymphoma, acute leukemia, and multiple myeloma. 1,40,41 Patients with high-grade lymphoma and acute promyelocytic leukemia seem to be at higher risk than those with other forms of lymphoma or leukemia.…”